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Leprosy is a chronic infection caused by
Mycobacterium leprae that affects the periph-
eral nerves, skin, and potentially other
organs [1–5]. Although the worldwide
prevalence of leprosy has decreased in
the era of multi-drug therapy (MDT), the
global detection of new cases of leprosy
remains a concern, with more than
250,000 new cases of leprosy reported in
2007 [3]. The precise mechanism of
transmission of leprosy has not been
conclusively defined; however, it is likely
that this occurs through respiratory secre-
tions by untreated borderline lepromatous
and polar lepromatous cases [1,5]. Target
cells of infection are macrophages, histio-
cytes in the skin, and the nonmyelinating
and myelinating Schwann cells in the
peripheral nerve, leading to axonal dys-
function and demyelination [6]. Nerve
injury plays a central role in the patho-
genesis of leprosy, leading to functional
impairment and deformity of hands and
feet and the eyes [1,6]. Leprosy is
diagnosed by definite loss of sensation in
a hypopigmented or reddish skin patch, a
thickened peripheral nerve with loss of
sensation and muscle weakness in the
affected nerve, and presence of acid-fast
bacilli on skin smear or biopsy [1,4].
The immunological response to M.
leprae mounted by the host will determine
the different potential clinical states. The
Ridley-Joplin system uses clinical and
histopathological features and the bacteri-
ologic index and includes the polar
categories (lepromatous [LL] and tuber-
culoid [TT]) and the borderline states
(borderline tuberculoid [BT], borderline
borderline [BB], and borderline leproma-
tous [BL]) [1] (Table 1). In the polar
tuberculoid category, a Th1 type cell–
mediated immune response with a low
bacterial load is seen. Lepromatous states
are characterized by low cell-mediated
immunity and a higher bacterial load [5]
(Table 1). Clinically, patients with tuber-
culoid leprosy have a single or very few
hypopigmented macules or plaques with a
raised edge; they are dry, scaly, hairless,
and have reduced sensation; and only a
few peripheral nerves are commonly
enlarged [1]. Lepromatous leprosy is
characterized by widely and symmetrically
distributed skin macules, nodules, ery-
thematous papules, and diffuse skin infil-
tration; thickened peripheral nerves are
more frequently identified. Borderline
states represent a mixture of signs and
symptoms of the polar categories [1].
Description of Case A
A 31-year-old Brazilian male living in
the United States for the previous four
years presented with progressive crops of
new nontender nodules on all four ex-
tremitiesover a 16-monthperiod (Figures 1
and 2). He had more than ten nodules in
each limb, with some reaching 0.5–1.0 cm
in diameter. A 365-cm area of diffuse skin
infiltration was present in his left thigh. He
had referred numbness in the lower
extremities. He had thickened bilateral
ulnar nerves with mild sensory loss by
monofilament testing in the ulnar nerve
and peroneal nerve territories without any
nerve tenderness identified. His posterior
tibial nerves were also palpable. There was
no muscle weakness identified by volun-
tary muscle testing using the 0–5 modified
Medical Research Council scale. Nasal
mucosa was normal. Eyelid closure was
tested and there was no evidence of
lagopthalmos; eyelashes were normal. His
conjunctivae were pink. A skin biopsy
demonstrated a diffuse lymphocytic infil-
trate with multiple foamy macrophages.
Fite-Faraco staining showed multiple acid-
fast bacilli (Figure 3). A skin smear
demonstrated a bacterial index (BI) of 5.
The patient was diagnosed with leproma-
tous leprosy, using the Ridley-Joplin
staging system [1], or multibacillary lep-
rosy per the World Health Organization
(WHO) staging [2–5] (Table 1). He was
started on MDT consisting of dapsone
100 mg PO daily, rifampin 600 mg PO
daily, and clofazimine 50 mg PO daily. (In
the United States, the National Hansen’s
Disease Program recommends using daily
rifampin, while the rest of the world uses
rifampin once monthly with less than 1%
relapses [4].)
We recommended that he continue his
MDT until his BI (the BI is a logarithmic
scale used to assess response to MDT in
skin smears) decreased below 2 (dead
bacteria may be present in the skin up to
10 years). Despite the WHO recommen-
dation of 12 months of MDT for multi-
bacillary cases such as our patient, many
experts still advocate 24 months of MDT
for patients with a BI .4 at diagnosis [1].
Six months after the initiation of MDT,
patient A experienced the abrupt onset of
multiple new erythematous and ulcerated
skin nodules (1–2 cm) distributed in the
upper limbs, trunk, and right leg (Figure 4).
The original leprosy nodules remained as
they were. He also had a fever up to
39.5uC, swelling of his hands and feet, and
cervical lymphadenopathy. He had thick-
ened bilateral ulnar and peroneal nerves
with moderate sensory loss by monofila-
ment testing compared to his initial
baseline evaluation in the ulnar nerve
and peroneal nerve territories. There was
no nerve tenderness identified. There was
no muscle weakness identified by volun-
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amination of one new lesion showed
evidence of neutrophilic infiltration. He
had no clinical evidence of uveitis, arthri-
tis, or orchitis.
Based on the clinical history and signs,
our patient was diagnosed with a type 2
leprosy reaction [5] (Table 2). He was
treated with 60 mg of oral prednisone
daily tapered over a 12-week period [4]. A
6-week course of thalidomide 200 mg PO
daily was also used due to the severity of
the reaction, with rapid clinical improve-
ment (Table 3). His rifampin dose was
reduced to 600 mg monthly due to the
concomitant use of prednisone since
rifampin may lower prednisone serum
levels. Our patient presented a protracted
course with two more episodes of severe
type 2 reactions that were treated with a
similar corticosteroid regimen. A repeat
skin biopsy performed 12 months after
commencing MDT showed decreasing
numbers of acid-fast bacilli, and skin
smears showed a decreasing BI.
What Are Leprosy Reactions and
How Are They Diagnosed?
Reactional states represent a change in
the immunological state of a patient with
leprosy. These reactions are characterized
by inflammatory episodes of the skin,
nerves, and other organs that can occur
anytime within the course of leprosy, but
are often observed after starting treatment,
and can result in irreversible nerve dam-
age [2,4]. There are two main types of
reactions: type 1, or reversal reactions
(RR), and type 2 reactions, or erythema
nodosum leprosum (ENL) [5] (Table 2).
Type 1 reactions are considered to be
an upgrading in the cell-mediated immune
response to M. leprae [5]. These patients
have relatively few bacteria and low
antibody levels to M. leprae as compared
to lepromatous states [1]. Schwann cells
have been shown to express Toll-like
receptor 2 (TLR-2) and major histocom-
patiblity complex (MHC II) with antigen
presentation ability, resulting in CD4+ T
cell activation [1,7]. The incidence of type
1 reactions occurring as immune-reconsti-
tution syndromes among patients with
borderline leprosy co-infected with HIV/
AIDS receiving antiretroviral therapy
supports an upgrading of cell-mediated
immunity as a key pathogenic event in
type 1 reactions [8].
Type 2 reactions are characterized by
an inflammatory infiltrate of neutrophils
with associated vasculitis and/or pannicu-
litis [9]. Although it is accepted that a cell-
mediated component is required, the
ultimate pathogenesis results from deposi-
tion of antigen–antibody complexes in
tissues, leading to an acute inflammatory
response, particularly in nerves, skin, and
other organs with increased levels of
circulating TNF-a and IL-6 [9]. The
major T cell subtype identified during
type 2 reactions is the CD4+ lymphocyte
subset [9].
Type 1 reactions affect patients within
the borderline spectrum (BT, BB, and BL),
while type 2 reactions occur among
patients with BL and LL states [5]
(Tables 1 and 2). The higher the bacterial
load and the greater the infiltration of the
skin, the higher the risk of developing type
2 reactions [1,8]. For type 1 reactions,
starting MDT is considered the strongest
risk factor [1].
In the MDT era, reactions occur in
approximately 15%–39% of patients with
leprosy [10–12].
How Do Type 2 Reactions Present
Clinically?
The diagnosis of leprosy reactions is
based primarily on clinical history and
examination [1,5]. Type 2 reactions pre-




a TT BT BB BL
b LL
Type 1 Reaction No Yes Yes Yes No
Type 2 Reaction No No No Yes Yes
WHO classification is used for operational purposes in the field and it is based on the number of skin lesions;
Ridley-Joplin classification is an immunopathological and clinical classification.
Adapted from [5].
aRidley-Joplin classification: tuberculoid (TT); borderline tuberculoid (BT); borderline borderline (BB);
borderline lepromatous (BL); and lepromatous (LL).
bPatients with BL can develop both types of reactions.
doi:10.1371/journal.pntd.0000425.t001
Figure 1. Multiple non-tender nodules
(0.5–1.0 cm) in the right arm.
doi:10.1371/journal.pntd.0000425.g001
Figure 2. Multiple non-tender nodules
(0.5–1.0 cm) in the right leg.
doi:10.1371/journal.pntd.0000425.g002
Figure 3. Fite-Faraco staining of skin
biopsy demonstrating abundant acid-
fast bacilli inside foamy macrophages
(arrow).
doi:10.1371/journal.pntd.0000425.g003
Figure 4. Newly appeared and rapidly
ulcerating lesion in the right arm, ac-
companied with fever, cervical lymph-
adenopathy, and malaise.
doi:10.1371/journal.pntd.0000425.g004
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Leprosy Stage Type 1 Reaction–Reversal Reaction (RR) Type 2 Reaction–Erythema Nodosum Leprosum (ENL)
Occurs in borderline disease (BT, BB, BL)
a Occurs in BL and LL
a
Skin Acute onset of redness and swelling in leprosy skin lesions
and sometimes lesions may ulcerate. Marked edema of the
hands, feet, and face may occur. No new lesions appear.
New painful and tender red papules or nodules which occur in crops in limbs or trunk and
face. Ulceration of nodules may occur. Edema of the hands, feet, or face may occur. Original
leprosy skin patches remain as they were.
Nerve New nerve damage manifesting as numbness, or muscle
weakness in the hands, feet, or face. Pain or tenderness in
one or more nerves, with or without loss of nerve function.
b
New nerve damage manifesting as numbness,or muscleweakness in the hands, feet, or face.
Pain or tenderness in one or more nerves, with or without loss of nerve function.






aBT = borderline tuberculoid; BB=borderline borderline; BL=borderline lepromatous; LL=lepromatous.
bSometimes silent neuritis may be present, manifested by nerve function impairment (loss of sensations and/or muscle weakness) without skin inflammation.
cSkin biopsy may present some key features such as dermal edema, granuloma edema, and presence of giant cells and plasma cells.
dSkin biopsy may present a mixed dermal infiltrate of neutrophils and lymphocytes and fragmented bacilli in macrophages.
eFor mild reactions, non-steroidal anti-inflammatory drugs may be sufficient. Prednisone or prednisolone are used for severe signs and symptoms; for alternative
treatment options, see Table 2.
doi:10.1371/journal.pntd.0000425.t002











N Erythematous, mildly swollen skin lesions;
n op a i n f u lo rt e n d e rn e r v e s
N Painful swollen skin lesions; swollen lesions of the face; edema of hands,
feet, or face
N No lesions of the face; no edema of the
face, hands, or feet
N Diminished sensation or muscle weakness in hands and/or feet





e single daily dose then
tapered over 12–20 weeks
N In selected cases, clofazimine is added to prednisone as a steroid
sparing agent in a dose up to 300 mg daily for 6 weeks. If effective,






N No fever; minimal pain and no ulcerating
lesions
N Febrile systemic illness; painful or ulcerating skin lesions; marked
lymphadenitis;painful ortender nerves; diminished sensation or muscle
weakness of hands or feet; severe edema of hands or feet; iritis, scleritis,
arthritis, orchitis
N No painful or tender nerves; no eye problems
Treatment N Non-steroidal analgesics for 1–2 weeks N Prednisone or prednisolone 40–80 mg daily tapered to lowest dose
required to control the reaction
N This regimen may be repeated several times
if reaction remains mild
N Clofazimine may be used alone in patients intolerant to corticosteroids,
or in combination with corticosteroids in those with severe type 2
reactions at a dose of 300 mg daily for 12 weeks (can be divided three
times a day), and tapered to 100 mg twice a day for 12 weeks and then
100 mg once a day for 12–24 weeks
N Thalidomide 200–400 mg daily in divided doses is sometimes used




aDistinction between mild and severe reactions is clinical and based on the presence of one or more of the signs/symptoms listed.
bUse of steroids is recommended when patients have severe symptoms suggestive of new nerve damage (numbness and/or muscle weakness in the hands or feet).
MDT should be continued concomitantly to anti-reaction drugs. In those who have completed MDT, management of reactions does not require restarting MDT [2].
cPatients receiving corticosteroids need to be examined every week and the dose of corticosteroid reduced every 2 weeks.
dPrednisone and prednisolone are equivalent in dosing potency and can be used interchangeably (see http://www.globalrph.com/corticocalc.htm). Some countries
have availability of either prednisone or prednisolone [5].
eThe WHO recommended regimen of corticosteroids (prednisone) is 40 mg daily for weeks 1 and 2; followed by 30 mg daily for weeks 3 and 4; 20 mg daily for weeks5
and 6; 15 mg daily for weeks 7 and 8; 10 md daily for weeks 9 and 10, and 5 mg daily for weeks 11 and 12 [4].
fSevere type 2 reactions are often recurrent or chronic and therefore anti-reaction drug treatment may be adjusted according to the needs of the individual patient [11].
gWHO does not assist or support the use of thalidomide due to its teratogenic effects and its elevated cost. An additional argument is that most patients with type 2
reactions be can be successfully managed with the proper use of other anti-reaction drugs (corticosteroids and clofazimine) [4].
doi:10.1371/journal.pntd.0000425.t003
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ous nodules sometimes associated with
fever, malaise, arthralgias, neuritis, and
adenopathy, and occasionally uveitis, or-
chitis, or dactylitis [1,2,5] (Table 2). Type
2 reactions usually occur after a patient
with leprosy has been on MDT for months
or years. Histologically, skin biopsy spec-
imens may demonstrate a mixed dermal
infiltrate of neutrophils and lymphocytes
and fragmented bacilli in macrophages
[2,5,13].
Type 2 reactions often follow a pro-
tracted clinical course [13]. In fact, three
subtypes of type 2 reactions have been
identified depending on its clinical course:
acute single episode, multiple acute epi-
sodes, and chronic. Most cases tend to
become chronic [13].
What Is the Optimal Management of
Type 2 Reactions?
MDT should be continued concomi-
tantly to anti-reaction drugs in type 1 and
type 2 reactions. In those who have
completed MDT, management of reac-
tions does not require restarting MDT [2].
For mild reactions, non-steroidal anti-
inflammatory agents may be used
(Table 3) [5]. Corticosteroids (prednisone
or prednisolone) remain the standard of
care for the acute symptoms of severe type
2 reactions with daily regimens tapered
over a 12-week course [1,2,4,5]. However,
many patients require repeated treatment
for multiple acute episodes or long-term
corticosteroid use [2,13].
Thalidomide is sometimes used in
combination with corticosteroids for con-
trolling severe type 2 reactions [10]. Its
therapeutic effect has been associated with
transient immune stimulation of IL-2 and
interferon-c produced by activated CD4+
and CD8+ lymphocytes [14]. Nonetheless,
thalidomide has significant limitations for
widespread use: it is costly, unavailable in
many settings, and has significant side
effects (teratogenicity, sedation, neuropa-
thy, and thrombosis) [4].
Clofazimine is considered an anti-reac-
tion agent in addition to its role in MDT
against M. leprae (Table 3). Management of
type 2 reactions with clofazimine is
indicated in patients who are not respond-
ing satisfactorily to treatment with corti-
costeroids or when the risk of toxicity with
corticosteroids is high [2]; or as mono-
therapy when corticosteroids are contra-
indicated [4]. The total duration of
treatment with high dose clofazimine
should not exceed 12 months. Side effects
of clofazimine include gastrointestinal
symptoms and skin hyperpigmentation
[2,4].
The use of tumor necrosis factor
inhibitors (TNF-a inhibitors) has been
considered in patients with type 2 reac-
tions. However, the TNF-a inhibitor
infliximab has been associated with the
clinical development of leprosy and, upon
its discontinuation, the occurrence of type
1 reactions [15]. The effects of other TNF
inhibitors are not known. Azathioprine
has been successfully used in preventing
recurrences [16]. Mycophenolate mofetil
is not effective when used as a corticoste-
roid sparing agent [17].
Description of Case B
A 28-year-old Indian male, living in the
United States for 2 years, presented with
an 8-month history of multiple skin
plaques that were well defined with their
edges slightly raised, and scaly, and
localized mostly in the face, upper and
lower limbs, and trunk (Figure 5A). Some
of these plaques were anesthetic and dry.
The lesions range from 2 cm to 6 cm in
diameter, with the ones on the right thigh
being the largest. No thickened peripheral
nerves or nerve tenderness were identified.
Monofilament testing demonstrated mild
sensory loss, more in the right hand than
the left, and mainly in the distribution of
the ulnar nerve. There was no other
sensory loss detected at other sites and
there was no muscle weakness identified
by voluntary muscle testing using the 0–5
modified Medical Research Council scale.
Nasal mucosa was normal. There was no
evidence of madarosis with normal eye-
lashes, corneal reflexes, and eyelid closure;
his conjunctivae were pink. Fite-Faraco
stains of skin biopsy taken from one of the
lesions in the right elbow demonstrated
acid-fast organisms within histiocytes and
within nerve fibers. A diagnosis of border-
line tuberculoid was made (Tables 1 and 2)
and he began receiving MDT consisting of
rifampin 600 mg once a month, dapsone
100 mg daily, and clofazimine 50 mg
daily.
Almost 2 months after he began receiv-
ing MDT, he developed a sudden onset of
bilateral lower limb edema, with inflam-
mation of previously existent skin plaques
distributed in his four limbs and in the
trunk. No new skin lesions were identified
(Figure 5A). He also developed neuropath-
ic pain in his lower limbs. No thickened
peripheral nerves or nerve tenderness were
identified. Monofilament testing demon-
strated worsening sensory loss in the
distribution of the ulnar nerves, and new
mild sensory loss in the peroneal nerve
distribution bilaterally. His voluntary mus-
cle testing remained normal. At this point,
our patient was diagnosed with a type 1
reaction. Along with continuing his MDT,
he received a corticosteroid regimen
tapered over a 20-week period, resulting
in significant improvement (Figure 5B). He
completed a 6-month course of MDT and
has finished his prednisone tapered over a
9-month period.
How Do Type 1 Reactions Present
Clinically?
Type 1 reactions are characterized by
increasing swelling, erythema, and tender-
ness of previously existing skin lesions
accompanied by increased neuritis mani-
fested as pain or tenderness in one or more
nerves associated with pain and nerve
function impairment [2,5] (Table 2). In-
volvement of the face may result in facial
paralysis and lagopthalmos; when affecting
the eyes it may cause iritis and scleritis [5].
In type 1 reactions, some key features
identified on skin biopsies include dermal
Figure 5. Patient with a type 1 leprosy reaction. (A) Patient with borderline tuberculoid
leprosy with inflammation of previously existent skin plaques distributed in his four limbs and in
the thorax. (B) Improvement of inflammation of the skin findings after corticosteroid treatment.
doi:10.1371/journal.pntd.0000425.g005
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of giant cells and plasma cells [18].
What Is the Optimal Management of
a Type 1 Reaction?
The foremost priority in the manage-
ment of type 1 reactions is the treatment of
neuritis followed by decreasing acute
inflammation, easing pain, and reversing
nerve and eye damage [1,5]. Corticoste-
roids (prednisone or prednisolone) are the
standard of care [1,2–5]. WHO recom-
mends a regimen of corticosteroids ta-
pered over a 12-week period (Table 3) [4].
However, regimens of corticosteroids ta-
pered over a longer period (20 weeks) have
been shown to be more effective in
controlling type 1 reactions [1]. The most
commonly affected nerves are the facial,
ulnar, median, common peroneal, facial,
and posterior tibial.
If the reversal reaction becomes chron-
ic, requiring high doses of corticosteroids
for extended periods, adjunctive clofazi-
mine, started at 100 mg three times daily
and subsequently tapered over many
months, may be used (Table 3) [5].
Cyclosporine-A and methrotexate may
be effective in patients intolerant to
corticosteroids [19,20].
Discussion of Cases A and B
The clinical management of leprosy
reactions is challenging. Leprosy reactions
occur among patients with borderline and
lepromatous leprosy and may occur prior
to the initiation of MDT, during MDT, or
even years after its completion. Corticoste-
roids are considered the standard of care
for managing type 1 and type 2 reactions,
sometimes in combination with clofazimine
or thalidomide. Long-term follow-up of
patients diagnosed with leprosy and who
have suffered leprosy reactions is needed,
even after completion of MDT. Further
research regarding their pathogenesis and
optimal medical management is warranted.
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Key Learning Points
N Leprosy reactions contribute significantly to neurological sequelae and
functional and anatomical impairment.
N Leprosy reactions occur among patients with borderline and lepromatous
leprosy and may occur prior to the initiation of MDT, during MDT, or even years
after its completion.
N Early detection and effective treatment of reactions is critical to prevent nerve
damage.
N The treatment of choice for both types of reactions (and neuritis) is
corticosteroids.
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